

# David Feifel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6312328/publications.pdf>

Version: 2024-02-01

46  
papers

1,334  
citations

448610

19  
h-index

388640

36  
g-index

46  
all docs

46  
docs citations

46  
times ranked

1894  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intranasal oxytocin modulates the salience network in aging. <i>NeuroImage</i> , 2022, 253, 119045.	2.1	3
2	Age and intranasal oxytocin effects on trust-related decisions after breach of trust: Behavioral and brain evidence.. <i>Psychology and Aging</i> , 2021, 36, 10-21.	1.4	10
3	Safety and tolerability of chronic intranasal oxytocin in older men: results from a randomized controlled trial. <i>Psychopharmacology</i> , 2021, 238, 2405-2418.	1.5	8
4	Seizure risk with repetitive TMS: Survey results from over a half-million treatment sessions. <i>Brain Stimulation</i> , 2021, 14, 965-973.	0.7	14
5	Reply to Tendler etÂal. <i>Brain Stimulation</i> , 2021, 14, 1216-1217.	0.7	0
6	Chronic oxytocin administration as a tool for investigation and treatment: A cross-disciplinary systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 108, 1-23.	2.9	44
7	Safety of Repeated Administration of Parenteral Ketamine for Depression. <i>Pharmaceuticals</i> , 2020, 13, 151.	1.7	17
8	Development of an innovative adult attention-deficit hyperactivity disorder clinic. <i>Mental Health Clinician</i> , 2020, 10, 296-300.	0.5	6
9	Oxytocin alters patterns of brain activity and amygdalar connectivity by age during dynamic facial emotion identification. <i>Neurobiology of Aging</i> , 2019, 78, 42-51.	1.5	22
10	Network Meta-analysis in Mental Health Research. <i>JAMA Psychiatry</i> , 2017, 74, 850.	6.0	2
11	Exposure to salient, dynamic sensory stimuli during development increases distractibility in adulthood. <i>Scientific Reports</i> , 2016, 6, 21129.	1.6	4
12	Oxytocinâ€™s effect on resting-state functional connectivity varies by age and sex. <i>Psychoneuroendocrinology</i> , 2016, 69, 50-59.	1.3	68
13	Breaking S&ad: unleashing the breakthrough potential of Ketamine's Rapid Antidepressant Effects. <i>Drug Development Research</i> , 2016, 77, 489-494.	1.4	12
14	Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil. <i>Journal of Visualized Experiments</i> , 2016, , .	0.2	3
15	Potential of Oxytocin in the Treatment of Schizophrenia. <i>CNS Drugs</i> , 2016, 30, 193-208.	2.7	69
16	A Review of Oxytocinâ€™s Effects on the Positive, Negative, and Cognitive Domains of Schizophrenia. <i>Biological Psychiatry</i> , 2016, 79, 222-233.	0.7	93
17	INTRANASAL OXYTOCIN ADMINISTRATION PRIOR TO EXPOSURE THERAPY FOR ARACHNOPHOBIA IMPEDES TREATMENT RESPONSE. <i>Depression and Anxiety</i> , 2015, 32, 400-407.	2.0	39
18	Limited evidence that benzodiazepines are beneficial in the treatment of disturbed behaviour. <i>Evidence-Based Mental Health</i> , 2013, 16, 111-111.	2.2	0

#	ARTICLE	IF	CITATIONS
19	Oxytocin as a Potential Therapeutic Target for Schizophrenia and Other Neuropsychiatric Conditions. <i>Neuropsychopharmacology</i> , 2012, 37, 304-305.	2.8	31
20	The effects of oxytocin and its analog, carbetocin, on genetic deficits in sensorimotor gating. <i>European Neuropsychopharmacology</i> , 2012, 22, 374-378.	0.3	35
21	Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia. <i>Schizophrenia Research</i> , 2012, 139, 207-210.	1.1	105
22	Promise and Pitfalls of Animal Models of Schizophrenia. <i>Current Psychiatry Reports</i> , 2010, 12, 327-334.	2.1	26
23	Adjunctive Intranasal Oxytocin Reduces Symptoms in Schizophrenia Patients. <i>Biological Psychiatry</i> , 2010, 68, 678-680.	0.7	271
24	Effects of neurotensin-2 receptor deletion on sensorimotor gating and locomotor activity. <i>Behavioural Brain Research</i> , 2010, 212, 174-178.	1.2	5
25	The acute and subchronic effects of a brain-penetrating, neurotensin-1 receptor agonist on feeding, body weight and temperature. <i>Neuropharmacology</i> , 2010, 58, 195-198.	2.0	48
26	The use of placebo-controlled clinical trials for the approval of psychiatric drugs: part I-statistics and the case for the "greater good". <i>Psychiatry</i> , 2009, 6, 41-3.	0.3	4
27	The Use of Placebo-Controlled Clinical Trials for the Approval of Psychiatric Drugs: Part II-Ethical Considerations Related to the Individual Participant. <i>Psychiatry</i> , 2009, 6, 19-25.	0.3	2
28	The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance. <i>Psychopharmacology</i> , 2008, 200, 197-203.	1.5	24
29	Attention-Deficit/Hyperactivity Disorder in Adults: Recognition and Diagnosis of this Often-Overlooked Condition. <i>Postgraduate Medicine</i> , 2008, 120, 39-47.	0.9	7
30	Why Diagnose and Treat ADHD in Adults?. <i>Postgraduate Medicine</i> , 2008, 120, 13-15.	0.9	5
31	Transforming the psychiatric inpatient unit from short-term pseudo-asylum care to state-of-the-art treatment setting. <i>Psychiatry</i> , 2008, 5, 47-50.	0.3	2
32	More depressing news on antidepressants: should we panic?. <i>Psychiatry</i> , 2008, 5, 35-6.	0.3	2
33	The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats. <i>Behavioural Brain Research</i> , 2007, 181, 278-286.	1.2	42
34	The Effects of Cross-Fostering on Inherent Sensorimotor Gating Deficits Exhibited by Brattleboro Rats. <i>Journal of General Psychology</i> , 2007, 134, 173-182.	1.6	17
35	ADHD in adults: the invisible rhinoceros. <i>Psychiatry</i> , 2007, 4, 60-2.	0.3	1
36	An atomoxetine tutorial. <i>Psychiatry</i> , 2007, 4, 35-8.	0.3	0

#	ARTICLE	IF	CITATIONS
37	Time to feel good: the therapeutic time course of antidepressants. <i>Psychiatry</i> , 2007, 4, 25-7.	0.3	0
38	When common clinical practice meets evidence-based medicine. <i>Psychiatry</i> , 2006, 3, 36-8.	0.3	1
39	Reversal of Sensorimotor Gating Deficits in Brattleboro Rats by Acute Administration of Clozapine and a Neurotensin Agonist, but not Haloperidol: a Potential Predictive Model for Novel Antipsychotic Effects. <i>Neuropsychopharmacology</i> , 2004, 29, 731-738.	2.8	67
40	Inhibitory deficits in ocular motor behavior in adults with attention-deficit/hyperactivity disorder. <i>Biological Psychiatry</i> , 2004, 56, 333-339.	0.7	68
41	Altered extracellular dopamine concentration in the brains of cholecystokinin-A receptor deficient rats. <i>Neuroscience Letters</i> , 2003, 348, 147-150.	1.0	28
42	A Systemically Administered Neurotensin Agonist Blocks Disruption of Prepulse Inhibition Produced by a Serotonin-2A Agonist. <i>Neuropsychopharmacology</i> , 2003, 28, 651-653.	2.8	36
43	Sensorimotor gating effects produced by repeated dopamine agonists in a paradigm favoring environmental conditioning. <i>Psychopharmacology</i> , 2002, 162, 138-146.	1.5	5
44	Startle and Sensorimotor Gating in Rats Lacking CCK-A Receptors. <i>Neuropsychopharmacology</i> , 2001, 24, 663-670.	2.8	18
45	Antipsychotic Potential of CCK-Based Treatments: An Assessment Using the Prepulse Inhibition Model of Psychosis. <i>Neuropsychopharmacology</i> , 1999, 20, 141-149.	2.8	38
46	Attention-deficit hyperactivity disorder in adults. <i>Postgraduate Medicine</i> , 1996, 100, 207-218.	0.9	32